• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    12/28/23 12:31:16 PM ET
    $BACK
    $BBLG
    $BJDX
    $CING
    Medical Specialities
    Health Care
    Industrial Specialties
    Health Care
    Get the next $BACK alert in real time by email

    Gainers

    • Cingulate (NASDAQ:CING) shares moved upwards by 125.8% to $9.01 during Thursday's regular session. The market value of their outstanding shares is at $8.4 million.
    • SenesTech (NASDAQ:SNES) shares rose 107.53% to $1.79. The market value of their outstanding shares is at $1.3 million.
    • Jin Medical International (NASDAQ:ZJYL) stock moved upwards by 58.53% to $195.0. The company's market cap stands at $1.5 billion.
    • Microbot Medical (NASDAQ:MBOT) shares rose 36.71% to $1.8. The market value of their outstanding shares is at $21.1 million.
    • Ocean Biomedical (NASDAQ:OCEA) shares rose 30.51% to $0.78. The company's market cap stands at $26.7 million.
    • Bone Biologics (NASDAQ:BBLG) shares moved upwards by 27.53% to $5.93. The company's market cap stands at $3.1 million.

    Losers

    • CytoSorbents (NASDAQ:CTSO) shares decreased by 38.7% to $1.0 during Thursday's regular session. The market value of their outstanding shares is at $52.1 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock decreased by 29.18% to $1.24. The market value of their outstanding shares is at $1.5 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) stock decreased by 29.16% to $1.92. The market value of their outstanding shares is at $45.9 million.
    • IMAC Hldgs (NASDAQ:BACK) shares fell 23.71% to $2.06. The market value of their outstanding shares is at $2.3 million.
    • P3 Health Partners (NASDAQ:PIII) shares declined by 19.55% to $1.4. The market value of their outstanding shares is at $161.3 million.
    • NeoGenomics (NASDAQ:NEO) shares decreased by 18.49% to $16.71. The company's market cap stands at $2.1 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACK
    $BBLG
    $BJDX
    $CING

    CompanyDatePrice TargetRatingAnalyst
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    NeoGenomics Inc.
    $NEO
    7/30/2025Buy → Neutral
    BTIG Research
    NeoGenomics Inc.
    $NEO
    7/29/2025Outperform → Mkt Perform
    William Blair
    NeoGenomics Inc.
    $NEO
    5/15/2025Neutral
    Guggenheim
    NeoGenomics Inc.
    $NEO
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    NeoGenomics Inc.
    $NEO
    1/13/2025Buy → Hold
    The Benchmark Company
    More analyst ratings

    $BACK
    $BBLG
    $BJDX
    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

    ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. Operational and Clinical ProgressBluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. The Company confirmed that its SYMON™ II clinical study is progressing as planned, with on

    3/6/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year ended December 31, 2025, on Wednesday, March 25, 2026. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada mar

    3/5/26 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

    HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association's (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for health care professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness of Personal Protection Equipment (PPE), and education and training to minimize occupational r

    3/4/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Microbot Medical with a new price target

    Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50

    12/3/25 8:38:40 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lake Street resumed coverage on P3 Health Partners with a new price target

    Lake Street resumed coverage of P3 Health Partners with a rating of Buy and set a new price target of $20.00

    8/28/25 8:10:21 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Aunan Greg D

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    3/3/26 6:16:42 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 4 filed by EVP, GC & Business Development Olivo Alicia C

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    3/3/26 6:16:24 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 4 filed by Pres & Chief Operating Officer Stone Warren

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    3/3/26 6:16:05 PM ET
    $NEO
    Precision Instruments
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    SEC Filings

    View All

    SEC Form 10-K filed by Bluejay Diagnostics Inc.

    10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 4:02:15 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 9:21:49 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    3/4/26 8:30:44 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    Financials

    Live finance-specific insights

    View All

    CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year ended December 31, 2025, on Wednesday, March 25, 2026. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada mar

    3/5/26 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

    Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights   Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 million Fourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37

    2/17/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 5

    1/27/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $BACK
    $BBLG
    $BJDX
    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care